Our Science

Presentations

Dr Hecht on the Investigation of A2B530 in Germline HLA-A*02 Heterozygous Solid Tumors

Hecht J. R. Interview conducted on OncLive. May 2023.

Dr Simeone on the EVEREST-1 Trial Evaluating A2B530 in Solid Tumors

Simeone D. Interview conducted on OncLive. April 2023.

Mesothelin-specific CAR-T Cell Therapy with HLA-gated Safety Mechanism Selectively Kills Tumor Cells

Tokatlian T. Presentation at the JAX Journal Club. November 2022.

Breanna DiAndreth, PhD, on Improving Selective Targeting of Tumor Cells

DiAndreth A. Interview conducted at Onco Cell Therapy Summit (OCTS) USA 2022. June 2022.

The Future of Logic-gated Cell Therapy

Go W. Interview conducted at the 4th International Workshop on CAR-T (iwCAR-T 2022). April 2022.

Treating Solid Tumors With Personalized Immunotherapy: Julian Molina, MD, PhD

Molina J. Interview conducted at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhD

Molina J. Interview conducted at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

Tmod™ T cell Therapy Platform Overview

Kamb, A. Interviews conducted at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

BASECAMP-1: An Observational Study to Identify Relapsed Solid Tumor Patients with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH) and Leukapheresis for Future CAR T Cell Therapy

Molina J. Oral poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

Managing Clinical Safety and Toxicity for Improved Patient Outcomes

Go W. Oral presentation at CAR-TCR Summit 2021. August 2021.

Optimizing Efficiency in Trial Sponsor and Clinician Relationships

Geiger B, Matthews A, Melvin P, et al. Panel discussion at CAR-TCR Summit 2021. August 2021.

Next-generation Logic-gated Cell Therapy

Go W. Oral presentation at the International Workshop on CAR-T 2021. April 2021.

Engineered T Cells Directed at Tumors with Defined Allelic Loss

Hamburger A, DiAndreth B, Cui J, et al. Oral presentation at 3rd Cell Therapies and Immunotherapy Conference. October 2020.

Explore Our Pipeline